Protara Therapeutics, Inc.
TARA
$3.97
-$0.07-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -39.40% | -28.80% | -25.81% | -25.00% | -6.93% |
| Total Depreciation and Amortization | 11.14% | 9.04% | -1.68% | -1.42% | -4.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.11% | -17.89% | -31.96% | -39.09% | -36.09% |
| Change in Net Operating Assets | -538.41% | -173.40% | -77.82% | 78.47% | 12.98% |
| Cash from Operations | -56.93% | -57.41% | -38.42% | -34.14% | -14.53% |
| Capital Expenditure | 53.27% | -49.21% | -11.11% | 19.57% | -174.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -54.05% | -825.35% | -901.11% | -340.03% | -193.68% |
| Cash from Investing | -53.87% | -828.22% | -906.26% | -340.66% | -193.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -45.09% | -43.54% | 136.78% | 136.78% | -- |
| Repurchase of Common Stock | -146.35% | -365.06% | -365.06% | -68.18% | -86.41% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 92.54% | 88.53% | -126.73% | -133.78% | -- |
| Cash from Financing | -42.03% | -40.86% | 137.05% | 137.17% | 137,644.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -295.57% | -191.83% | -317.94% | -204.46% | 25.75% |